- Home
- PMVP vs EDAP Comparison
PMVP vs EDAP Comparison
Compare PMVP & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- EDAP
- Stock Information
- Founded
- PMVP 2013
- EDAP 1979
- Country
- PMVP United States
- EDAP France
- Employees
- PMVP N/A
- EDAP N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PMVP Health Care
- EDAP Health Care
- Exchange
- PMVP Nasdaq
- EDAP Nasdaq
- Market Cap
- PMVP 55.1M
- EDAP 53.8M
- IPO Year
- PMVP 2020
- EDAP 1997
- Fundamental
- Price
- PMVP $1.15
- EDAP N/A
- Analyst Decision
- PMVP Strong Buy
- EDAP Buy
- Analyst Count
- PMVP 1
- EDAP 3
- Target Price
- PMVP $5.00
- EDAP $8.50
- AVG Volume (30 Days)
- PMVP 278.5K
- EDAP 37.5K
- Earning Date
- PMVP 08-07-2025
- EDAP 08-27-2025
- Dividend Yield
- PMVP N/A
- EDAP N/A
- EPS Growth
- PMVP N/A
- EDAP N/A
- EPS
- PMVP N/A
- EDAP N/A
- Revenue
- PMVP N/A
- EDAP $67,840,467.00
- Revenue This Year
- PMVP N/A
- EDAP N/A
- Revenue Next Year
- PMVP N/A
- EDAP N/A
- P/E Ratio
- PMVP N/A
- EDAP N/A
- Revenue Growth
- PMVP N/A
- EDAP 3.69
- 52 Week Low
- PMVP $0.81
- EDAP $1.26
- 52 Week High
- PMVP $1.82
- EDAP $5.28
- Technical
- Relative Strength Index (RSI)
- PMVP 57.96
- EDAP 36.07
- Support Level
- PMVP $0.96
- EDAP $1.60
- Resistance Level
- PMVP $1.14
- EDAP $1.74
- Average True Range (ATR)
- PMVP 0.07
- EDAP 0.10
- MACD
- PMVP -0.00
- EDAP -0.01
- Stochastic Oscillator
- PMVP 65.28
- EDAP 27.59
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.